Shane Shapera

List of Publications by Year
in descending order

34 papers	645 citations	623734 14 h-index	610901 24 g-index
34 all docs	34 docs citations	34 times ranked	805 citing authors

#	Article	IF	Citations
1	Accuracy and Reliability of Internet Resources for Information on Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 218-225.	5.6	98
2	Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT). Clinical Lung Cancer, 2018, 19, e219-e226.	2.6	57
3	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078.	0.8	57
4	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal, 2022, 60, 2102571.	6.7	57
5	Procedure volume and mortality after surgical lung biopsy in interstitial lungÂdisease. European Respiratory Journal, 2019, 53, 1801164.	6.7	54
6	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	45
7	Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 1405-1415.	0.8	44
8	Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax, 2021, 76, 37-43.	5.6	28
9	Development of the Functional Assessment of Cancer Therapyâ€“Immune Checkpoint Modulator (FACTâ€ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. Cancer, 2020, 126, 1550-1558.	4.1	26
10	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1320-1329.	0.8	25
11	Idiopathic Pulmonary Fibrosis: A Review of Disease, Pharmacological, and Nonpharmacological Strategies With a Focus on Symptoms, Function, and Health-Related Quality of Life. Journal of Pain and Symptom Management, 2020, 59, 1362-1378.	1.2	20
12	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322.	3.6	18
13	Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease. Lung, 2019, 197, 277-284.	3.3	17
14	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.5	15
15	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895.	0.8	14
16	Multi-dimensional scores to predict mortality in patients with idiopathic pulmonary fibrosis undergoing lung transplantation assessment. Respiratory Medicine, 2017, 125, 65-71.	2.9	13
17	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644.	2.3	12
18	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.5	8

#	Article	IF	Citations
19	Correlation of respiratory oscillometry with CT image analysis in a prospective cohort of idiopathic pulmonary fibrosis. BMJ Open Respiratory Research, 2022, 9, e001163.	3.0	7
20	Costs of Workplace Productivity Loss in Patients with Connective Tissue Diseaseâ€“associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	3.2	5
21	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	3.6	5
22	Feasibility and Outcomes of a Standardized Management Protocol for Acute Exacerbation of Interstitial Lung Disease. Lung, 2021, 199, 379-387.	3.3	4
23	Diagnostic Disparity of Previous and Revised American Thoracic Society Guidelines for Idiopathic Pulmonary Fibrosis. Canadian Respiratory Journal, 2015, 22, 86-90.	1.6	3
24	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 147-155.	0.5	3
25	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	2.9	3
26	What to Do with All of These Lung Nodules?. Canadian Respiratory Journal, 2014, 21, e52-e54.	1.6	2
27	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 226-228.	0.5	2
28	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Canadian Respiratory Journal, 2015, 22, 308-308.	1.6	1
29	Diagnostic criteria for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2018, 6, e6.	10.7	1
30	Management of idiopathic pulmonary fibrosis: A survey of Canadian respirologists. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 165-173.	0.5	1
31	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 257-258.	0.5	0
32	Real-world patterns of pirfenidone use and safety in patients with idiopathic pulmonary fibrosis in Canada: Data from INSPIRATION PLUS. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 25-30.	0.5	0
33	EFFICACY AND SAFETY OF NINTEDANIB IN US/CANADIAN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: FURTHER ANALYSES OF THE INBUILD TRIAL. Chest, 2020, 158, A2613-A2615.	0.8	0
34	Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021015.	0.2	0